Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[MDR reversing drugs for clinical development]

T Tsuruo1

  • 1Institute of Molecular and Cellular Biosciences, University of Tokyo.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 1, 1994
PubMed
Summary

New drug candidates, MS-209 and PSC-833, effectively reverse multidrug resistance (MDR) by interacting with P-glycoprotein. These compounds show promise for clinical applications due to their efficacy and potential for minimal side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis.

Blood·2000
Same author

Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.

Cancer research·2000
Same author

Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression.

Annals of oncology : official journal of the European Society for Medical Oncology·2000
Same author

Analysis of novel metastasis-associated gene TI-227.

Japanese journal of cancer research : Gann·2000
Same author

Retinoblastoma susceptibility protein, Rb, possesses multiple BRCT-Ws, BRCA1 carboxyl-terminus-related W regions with DNA break-binding activity.

Oncogene·2000
Same author

MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer.

The oncologist·2000

Area of Science:

  • Pharmacology
  • Cancer Biology
  • Drug Discovery

Background:

  • Multidrug resistance (MDR) remains a significant challenge in cancer therapy.
  • Verapamil was identified as an MDR-reversing agent in 1981, spurring research into similar compounds.
  • Effective MDR-reversing agents with minimal side effects are highly sought after.

Purpose of the Study:

  • To identify and evaluate novel compounds capable of reversing multidrug resistance.
  • To investigate the mechanism of action of potential MDR-reversing agents.
  • To assess the in vitro and in vivo efficacy of candidate MDR-reversing drugs.

Main Methods:

  • Screening of compounds for MDR-reversing activity.
  • In vitro assays to evaluate drug interaction with P-glycoprotein.
  • In vivo studies to confirm therapeutic efficacy and safety.

Main Results:

  • MS-209 and PSC-833 were identified as potent MDR-reversing agents.
  • Both compounds demonstrated direct interaction with P-glycoprotein.
  • Significant MDR-reversing effects were observed in both in vitro and in vivo models.

Conclusions:

  • MS-209 and PSC-833 exhibit promising MDR-reversing properties.
  • Their direct interaction with P-glycoprotein supports their mechanism of action.
  • These compounds represent potential candidates for future clinical development in overcoming MDR.

Related Experiment Videos